SOURCE: NuLife Sciences, Inc.

NuLife Sciences, Inc. Logo

August 31, 2017 08:30 ET

NuLife Announces Establishment of Wound Care Subsidiary, NuLife Medical Inc.

Wound Care Projected to be $20 Billion Market Worldwide by 2021

SAN CLEMENTE, CA--(Marketwired - August 31, 2017) - NuLife Sciences (OTCQB: NULF) through the company's wholly-owned subsidiary, NuLife BioMed, Inc., today announced it has established a wholly-owned subsidiary, NuLife Medical Inc., to focus exclusively on applying their proprietary patented technology to the treatment of chronic wounds.

Wounds that resist closure or healing, such as diabetic foot ulcers, present significant risks to patients and are a substantial cost burden to the healthcare system. Preliminary application of the NuLife Technique to wound care suggests tremendous potential to help patients and provides healthcare professionals with a solution for addressing these life threatening chronic wounds. The global market for chronic and acute wound care is substantial, and growing rapidly. Estimates suggest it is expected to exceed $20 billion by 2021.

"This represents the second application of the NuLife platform," said John Hollister, NuLife Sciences Chief Executive Officer. "Our new wound care subsidiary is an opportunity to help many people by addressing another life altering challenge. We are exploring ways to develop this model both within the United States and outside the United States, as major market opportunities exist in Latin America and Asia as well."

About NuLife Sciences

NuLife Sciences Inc. (OTCQB: NULF) is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit

Safe Harbor

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond the Company's control. The Company's actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this press release. All statements, other than statements of historical facts, included in this press release regarding the Company's growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements. When used in this press release, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "project," "plan" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements in this press release are reasonable, the Company cannot assure potential investors that these plans, intentions or expectations will be achieved. The Company discloses important factors that could cause the Company's actual results to differ materially from its expectations under "Risk Factors" and elsewhere in this press release. These cautionary statements qualify all forward-looking statements attributable to the Company or persons acting on its behalf.

Contact Information